Who is sponsoring NCT05417646?

NCT05417646 is sponsored by Steno Diabetes Center Copenhagen.

What drugs are being tested in NCT05417646?

Interventions in NCT05417646: Hyperglycaemic clamp, Placebo, Empagliflozin.

What condition does NCT05417646 study?

NCT05417646 studies Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes.

Is NCT05417646 still recruiting?

NCT05417646 is currently completed. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT05417646: MOD3ST-CLAMP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Completed NA Last updated 27 July 2023

What this trial tests

NA trial testing Hyperglycaemic clamp in Maturity-Onset Diabetes of the Young, Type 3 in 21 participants. Completed in 14 June 2023.

Timeline

22 June 2022

Primary endpoint
14 June 2023

14 June 2023

Quick facts

Lead sponsor	Steno Diabetes Center Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	21
Start date	22 June 2022
Primary completion	14 June 2023
Estimated completion	14 June 2023
Sites	1 location across Denmark

Drugs / interventions tested

Hyperglycaemic clamp
Placebo
Empagliflozin (empagliflozin) — full drug profile →

Conditions studied

Maturity-Onset Diabetes of the Young, Type 3 — all drugs for Maturity-Onset Diabetes of the Young, Type 3 →
Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Steno Diabetes Center Copenhagen — full company profile →

Who can join

18 and older, any sex, with Maturity-Onset Diabetes of the Young, Type 3 or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes. The most common cause of MODY is due to mutations in the gene hepatocyte nuclear factor 1 alpha (HNF1A) and is consequently named HNF1A-MODY (or MODY3). HNF1A-MODY is associated with urinary excretion of glucose at lower blood glucose levels compared to other types of diabetes. Normally, glucose is reabsorbed by sodium-glucose cotransporter 2 (SGLT2), but SGLT2 is downregulated due to the mutation in HNF1A. Investigators aim to evaluate the impact of the decreased expression of SGLT2 on glucosuria in patients with HNF1A-MODY compared to patients with type 2 diabetes (T2D) using a single dose of an SGLT2 inhibitor during a glucose clamp experiment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.
Maagensen H, Jensen JS, Høyerup SO, Thuesen ACB, et al · · 2025 · cited 1× · PMID 40608360 · DOI 10.2337/dc25-0737

Verify or expand the search:

Other trials of Hyperglycaemic clamp

Trials testing the same drug.

NCT06393049 — Microdialysis and Jugular Bulb Glucose Profiles During Hyperglycaemic Clamping in Patients With Severe Acute Brain Injur · NA · completed

Other Steno Diabetes Center Copenhagen trials

Trials by the same sponsor.

NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
NCT07427251 — The Postprandial Hypo-Avoid Study · Phase 4 · not yet recruiting
NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
NCT06832059 — Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in T · NA · recruiting
NCT07377266 — The Impact of Changing to a New Child- and Family-centered Outpatient Diabetes Clinic Focusing on Early Involvement of t · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05417646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Steno Diabetes Center Copenhagen
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing